Non Small Cell Lung Cancer Clinical Trials

204 studies are recruiting for non small cell lung cancer in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies, page 5

1. A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer

   The researchers are doing this study to find out whether the combination of tepotinib and ivonescimab is a safe and effective treatment for people with non-small cell lung cancer (NSCLC) that is positive for METex14 skipping. The researchers will test up to two different doses of tepotinib in combi…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT07619339 on ClinicalTrials.gov

2. TT-4 and TT-10 as Single Agents and in Combination in Subjects With Advanced Selected Solid Tumors and Pleural Mesothelioma

   The goal of this clinical trial is to evaluate TT-10, TT-4 and TT-10 + TT-4, (Dual Blockade) in participants with advanced selected solid tumors, who have failed or are not eligible for standard of care. The main questions it aims to answer are: 1. To evaluate the safety and tolerability of TT-10, …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   USC Norris Comprehensive Cancer Center, Los Angeles, California

   Locations

   2 in total

   Run by

   Portage Biotech

   See if you can join NCT04969315 on ClinicalTrials.gov

3. Using Urine Samples to Identify Lung Cancer

   The researchers are doing this study to test the ability of an animal biosensor platform (ABP) to detect NSCLC. Participants in this study will either be diagnosed with NSCLC, suspected to have NSCLC, or have not been diagnosed or suspected to have NSCLC. The ABP test uses laboratory animals that a…

   Stage

   Not phased

   Ages

   18 to 90

   Site

   Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge, New Jersey

   Locations

   7 in total

   Run by

   Memorial Sloan Kettering Cancer Center

   See if you can join NCT06033248 on ClinicalTrials.gov

4. Effects of Infusion Timing on Treatment Response in Solid Tumors

   This study evaluates whether the time of day when immunotherapy is given affects clinical outcomes. It includes patients eligible for PD-1 (programmed cell death protein 1) or PD-L1 (programmed death-ligand 1) inhibitor treatment who have either advanced or metastatic non-small cell lung cancer (NS…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

   Run by

   UNC Lineberger Comprehensive Cancer Center

   See if you can join NCT07630168 on ClinicalTrials.gov

5. Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

   Prospective clinical study designed to evaluate damage to the heart after receiving standard of care chemotherapy and radiation therapy for locally advanced Non-Small Cell Lung Cancer (NSCLC).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana

   Run by

   Indiana University

   See if you can join NCT07761910 on ClinicalTrials.gov

6. ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

   The purpose of ORACLE is to demonstrate the ability of a novel ctDNA assay developed by Guardant Health to detect recurrence in individuals treated for early-stage solid tumors. It is necessary that ctDNA test results are linked to clinical outcomes in order to demonstrate clinical validity for rec…

   Stage

   Not phased

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   57 in total

   Run by

   Guardant Health, Inc.

   See if you can join NCT05059444 on ClinicalTrials.gov

7. SIBYL: obServation of Therapy Response With lIquid BiopsY evaLuation

   The purpose of SIBYL is to generate clinical validity data for the ability of a future version of Guardant360 developed by Guardant Health to measure response to systemic therapy in patients with unresectable advanced solid tumors. It is necessary to collect clinical data points and treatment outco…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Orchard Healthcare Research Inc., Skokie, Illinois

   Run by

   Guardant Health, Inc.

   See if you can join NCT05935384 on ClinicalTrials.gov

8. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

   The main purpose of this study is to find out whether the study drug, LY4050784, is safe, tolerable and effective in participants alone or in combination with other anticancer agents. In addition, with locally advanced or metastatic solid tumors with a BRG1 (Brahma-related gene 1, also known as SMA…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UCLA, Santa Monica, California

   Locations

   33 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06561685 on ClinicalTrials.gov

9. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

   This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpr…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth Research Institute, Scottsdale, Arizona

   Locations

   15 in total

   Run by

   Cogent Biosciences, Inc.

   See if you can join NCT07361562 on ClinicalTrials.gov

10. Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

    A first in human study to evaluate the safety and preliminary antitumor activity of BBO-8520, a KRAS G12C (ON and OFF) inhibitor, as a single agent and in combination with pembrolizumab and BBO-10203 in subjects with locally advanced and unresectable or metastatic non-small cell lung cancer with a …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    O'Neal Comprehensive Cancer Center at UAB, Birmingham, Alabama

    Locations

    38 in total

    Run by

    TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)

    See if you can join NCT06343402 on ClinicalTrials.gov

11. A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NRAS-mutated advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The Angeles Clinic, Los Angeles, California

    Locations

    48 in total

    Run by

    Pierre Fabre Medicament

    See if you can join NCT04913285 on ClinicalTrials.gov

12. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Mayo Clinic, Phoenix, Arizona

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

13. A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue

    The purpose of this study is to find out whether lattice radiation therapy (LRT) is an effective radiation therapy technique when compared to standard stereotactic body radiation therapy (SBRT). The study will also study how the different radiation therapy techniques (LRT and SBRT) affect how many …

    Stage

    Not phased

    Ages

    18 and older

    Site

    Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05837767 on ClinicalTrials.gov

14. A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

    A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who h…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Miami, Coral Gables, Florida

    Locations

    11 in total

    Run by

    Ankyra Therapeutics, Inc

    See if you can join NCT07027514 on ClinicalTrials.gov

15. FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

    This is a Phase 1 study of FT836 administered in participants with advanced solid tumors. The primary objectives of the study are to evaluate the safety and tolerability of FT836 with or without chemotherapy and/or trastuzumab or cetuximab, and to determine the recommended phase 2 dose (RP2D) of FT…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    UC San Diego Moores Cancer Center, La Jolla, California

    Locations

    5 in total

    Run by

    Fate Therapeutics

    See if you can join NCT07216105 on ClinicalTrials.gov

16. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Los Alamitos, California

    Locations

    167 in total

    Run by

    AstraZeneca

    See if you can join NCT06350097 on ClinicalTrials.gov

17. Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer

    This is a phase 2, pragmatic, 1:1 randomized, open-label study that evaluates risk-adapted, proteomic-guided systemic therapy to improve 12-month progression free survival (PFS) among patients with previously untreated advanced non-small cell lung cancer.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Enloe Health Regional Cancer Center, Chico, California

    Locations

    4 in total

    Run by

    University of California, Davis

    See if you can join NCT07250477 on ClinicalTrials.gov

18. BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab

    This single-arm phase 2 study will enroll patients with resectable and operable stage IB - III non-small cell lung cancer and treat them with pre-operative ipilimumab + nivolumab plus low-dose stereotactic body radiation therapy (SBRT) delivered concurrently. Only patients who proceed to surgery wi…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rhode Island Hospital, Providence, Rhode Island

    Run by

    Brown University

    See if you can join NCT04933903 on ClinicalTrials.gov

19. Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC

    The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Florida Clinical Trials Group, LLC, Plantation, Florida

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT07777822 on ClinicalTrials.gov

20. A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

    The purpose of this study is to assess the safety, tolerability, and recommended dose(s) of BMS-986340 as monotherapy and in combination with nivolumab, docetaxel, or Pumitamig in participants with advanced solid tumors. This study is a first-in-human (FIH) study of BMS-986340 in participants with …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Community Cancer Institute, Clovis, California

    Locations

    47 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT04895709 on ClinicalTrials.gov

21. Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial

    This research is being done to test a combination of two drugs, Izalontamab Brengitecan (iza-bren) and Adagrasib, in patients with advanced KRAS G12C-mutant NSCLC that hasn't responded to other treatments. The purpose is to see if this combination works better than existing treatments for people wh…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Texas M. D. Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT07382726 on ClinicalTrials.gov

22. Cancer-related Fatigue During Maintenance Immunotherapy for Non-small Cell Lung Cancer (NSCLC): a Qualitative Study

    The purpose of this research is to understand cancer related fatigue in patients with non-small cell lung cancer (NSCLC), who are being treated with an immune checkpoint inhibitor.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Atrium Health Levine Cancer, Charlotte, North Carolina

    Locations

    2 in total

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT06567704 on ClinicalTrials.gov

23. Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer

    The purpose of this study is to examine the combination of osimertinib and carotuximab to assess the safety and find the recommended dose for treatment of advanced EGFR-mutated non-small cell lung cancer (NSCLC). Safety and tolerability will be measured by the number of dose-limiting toxicities, ac…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Cedars-Sinai Cancer at Beverly Hills (THO), Beverly Hills, California

    Locations

    5 in total

    Run by

    Karen Reckamp, MD, MS

    See if you can join NCT05401110 on ClinicalTrials.gov

24. Precise Exercise Regimen for Cancer Care (PERCC): A Pilot Study

    The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

    Stage

    Not phased

    Ages

    18 and older

    Site

    Dana-Farber Cancer Institute, Boston, Massachusetts

    Run by

    Dana-Farber Cancer Institute

    See if you can join NCT07412041 on ClinicalTrials.gov

25. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    City of Hope, Duarte, California

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov